Is Tyra Biosciences (TYRA) Undervalued As SURF302 Data Expectations Lift Interest?Simplywall·8 hours agoTYRA+15.25%
Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45Tip Ranks·2 days ago, 03:15 PMTYRA+15.25%
Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9PUBT·2 days ago, 12:01 PMTYRA+15.25%
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 | TYRA Stock NewsStockTitan·2 days ago, 04:00 AMTYRA+15.25%
Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRAMarket Beat·Aug 15 at 10:32 AMTYRA+15.25%
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% UpsideTradingView·Aug 11 at 02:20 PMTYRA+15.25%
Tyra Biosciences (TYRA) Projected to Announce Earnings on ThursdayMarket Beat·Aug 6 at 06:56 AMTYRA+15.25%
Tyra Biosciences shares are trading lower after the company reported worse-than-expected Q2 EPS results.benzinga_article·Aug 5 at 01:12 PMTYRA+15.25%
Tyra Biosciences Q2 FY26 net loss widens to $45.56 million; R&D expenses climb to $39.2 millionPUBT·Aug 4 at 08:22 PMTYRA+15.25%
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.8, Implies 96% UpsideTradingView·Jun 10 at 01:20 PMTYRA+15.25%
